Commission consults on new types of fees payable to EMA under EU pharmacovigilance law
This article was originally published in SRA
Executive Summary
The European Commission is seeking feedback on new types of fees that drug companies will have to pay to the European Medicines Agency under the provisions of the EU pharmacovigilance legislation1,2. While the fees are critical to the EMA being able to fulfil its new responsibilities under the legislation, it could still be a couple of years before they are in place.